Detalhe da pesquisa
1.
Multi-Site Concordance of Diffusion-Weighted Imaging Quantification for Assessing Prostate Cancer Aggressiveness.
J Magn Reson Imaging
; 55(6): 1745-1758, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34767682
2.
Spatial discrimination of glioblastoma and treatment effect with histologically-validated perfusion and diffusion magnetic resonance imaging metrics.
J Neurooncol
; 136(1): 13-21, 2018 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-28900832
3.
Practical guidance to identify and troubleshoot suboptimal DSC-MRI results.
Front Radiol
; 4: 1307586, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38445104
4.
Identification of a single-dose, low flip angle based CBV threshold for fractional tumor burden (FTB) mapping in recurrent glioblastoma.
AJNR Am J Neuroradiol
; 2024 May 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38782593
5.
Effects of perfusion on diffusion changes in human brain tumors.
J Magn Reson Imaging
; 38(4): 868-75, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23389889
6.
Potent in vivo efficacy of oral gallium maltolate in treatment-resistant glioblastoma.
Front Oncol
; 13: 1278157, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38288102
7.
A cross-sectional study to test equivalence of low- versus intermediate-flip angle dynamic susceptibility contrast MRI measures of relative cerebral blood volume in patients with high-grade gliomas at 1.5 Tesla field strength.
Front Oncol
; 13: 1156843, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37799462
8.
Basal Ganglia Iron Content Increases with Glioma Severity Using Quantitative Susceptibility Mapping: A Potential Biomarker of Tumor Severity.
Tomography
; 8(2): 789-797, 2022 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35314642
9.
Case report: Fractional brain tumor burden magnetic resonance mapping to assess response to pulsed low-dose-rate radiotherapy in newly-diagnosed glioblastoma.
Front Oncol
; 12: 1066191, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36561526
10.
Magnetic Resonance Imaging Mapping of Brain Tumor Burden: Clinical Implications for Neurosurgical Management: Case Report.
Neurosurg Open
; 2(4): okab029, 2021 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-34661110
11.
Value of dynamic contrast perfusion MRI to predict early response to bevacizumab in newly diagnosed glioblastoma: results from ACRIN 6686 multicenter trial.
Neuro Oncol
; 23(2): 314-323, 2021 02 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-32678438
12.
Pulsed Reduced Dose Rate Radiotherapy in Conjunction With Bevacizumab or Bevacizumab Alone in Recurrent High-grade Glioma: Survival Outcomes.
Int J Radiat Oncol Biol Phys
; 108(4): 979-986, 2020 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32599030
13.
Evaluating the Use of rCBV as a Tumor Grade and Treatment Response Classifier Across NCI Quantitative Imaging Network Sites: Part II of the DSC-MRI Digital Reference Object (DRO) Challenge.
Tomography
; 6(2): 203-208, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32548297
14.
Evaluating Multisite rCBV Consistency from DSC-MRI Imaging Protocols and Postprocessing Software Across the NCI Quantitative Imaging Network Sites Using a Digital Reference Object (DRO).
Tomography
; 5(1): 110-117, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30854448
15.
ACRIN 6684: Multicenter, phase II assessment of tumor hypoxia in newly diagnosed glioblastoma using magnetic resonance spectroscopy.
PLoS One
; 13(6): e0198548, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29902200
16.
Toward uniform implementation of parametric map Digital Imaging and Communication in Medicine standard in multisite quantitative diffusion imaging studies.
J Med Imaging (Bellingham)
; 5(1): 011006, 2018 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-29134189
17.
Multisite concordance of apparent diffusion coefficient measurements across the NCI Quantitative Imaging Network.
J Med Imaging (Bellingham)
; 5(1): 011003, 2018 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-29021993
18.
ACRIN 6684: Assessment of Tumor Hypoxia in Newly Diagnosed Glioblastoma Using 18F-FMISO PET and MRI.
Clin Cancer Res
; 22(20): 5079-5086, 2016 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27185374
19.
Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial.
Neuro Oncol
; 17(8): 1148-56, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-25646027
20.
Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma.
Neuro Oncol
; 16(6): 880-8, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24431219